What is the treatment for Grover's disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Grover's Disease

Topical corticosteroids are the first-line treatment for Grover's disease, with medium- to high-potency formulations (such as triamcinolone or clobetasol) applied to the trunk and low-potency hydrocortisone reserved for facial lesions. 1, 2

First-Line Therapy

  • Apply medium- to high-potency topical corticosteroids (triamcinolone 0.1% or clobetasol 0.05%) to affected areas on the trunk twice daily for 3-4 weeks 1, 2, 3
  • Use low-potency hydrocortisone on facial lesions to avoid skin atrophy 4
  • Add topical vitamin D analogues as an alternative or adjunct to corticosteroids, which show good efficacy 1
  • Prescribe oral antihistamines for symptomatic relief of pruritus as needed 4, 1
  • Apply moisturizing emollients regularly to address xerosis, which can trigger disease 3, 5

Important caveat: If the rash is asymptomatic and stable, observation without treatment is acceptable since Grover's disease spontaneously resolves in 42% of cases within weeks to months 4, 2

Second-Line Therapy for Refractory Cases

When topical therapy fails after 4 weeks or disease is severe and widespread:

  • Systemic retinoids show an 86% response rate and are the preferred second-line option 2
  • Oral corticosteroids (prednisone 0.5-1 mg/kg/day) achieve a 64% response rate but carry more side effects 2
  • Phototherapy (PUVA or narrowband UVB) can be considered for resistant cases 1, 3

Disease Prevention Strategies

  • Avoid heat, sweating, and occlusive environments (bandages, tight clothing) which trigger acantholysis 3, 6
  • Minimize UV exposure as ultraviolet radiation exacerbates disease 3
  • Address xerosis with regular emollient use, particularly in winter months when disease is 4 times more common 3

Special Populations

In immunosuppressed patients (transplant recipients, chemotherapy patients):

  • The same topical corticosteroid approach applies as first-line 3, 5
  • Disease may resolve spontaneously within 2 weeks even without treatment modification 3
  • Consider reducing immunosuppression if clinically feasible, though this is rarely necessary 3

Common pitfall: Do not confuse Grover's disease with graft-versus-host disease in transplant patients—the evidence provided about GVHD management 4, 7, 8 is not applicable to Grover's disease, which is a distinct acantholytic dermatosis requiring different treatment.

Treatment Duration and Monitoring

  • Continue topical therapy for 3-4 weeks initially 3
  • Taper treatment as lesions resolve rather than stopping abruptly 2
  • Monitor for spontaneous resolution, which occurs in nearly half of cases 2
  • For chronic cases lasting years, maintain intermittent topical therapy as needed 1

References

Research

Grover disease: review of subtypes with a focus on management options.

International journal of dermatology, 2020

Research

Clinical features and treatments of transient acantholytic dermatosis (Grover's disease): a systematic review.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2020

Research

Grover's Disease in a Kidney Transplant Recipient.

Acta dermatovenerologica Croatica : ADC, 2019

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Monolateral Grover's Disease with Blaschkoid Distribution.

Acta dermatovenerologica Croatica : ADC, 2017

Guideline

Management of Graft-versus-Host Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment Guidelines for Acute Graft-Versus-Host Disease Post Liver Transplantation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.